Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: A randomized international trial

HIV Clinical Trials

Volumn 13, Issue 3, 2012, Pages 142-152

  Rodriguez Torres, Maribel ^a   Slim, Jihad ^b   Bhatti, Laveeza ^c   Sterling, Richard ^d   Sulkowski, Mark ^e   Hassanein, Tarek ^f   Serrão, Rosário ^g   Sola, Ricard ^h   Bertasso, Anne ⁱ   Passe, Sharon ⁱ   Stancic, Saray ⁱ  

^a Fundacion de Investigacion   (Puerto Rico)

^b ST MICHAEL S MEDICAL CENTER   (United States)

^c Westside Healthcare Center   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HOSPITAL DE SÃO JOÃO   (Portugal)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOFFMANN LA ROCHE INC   (United States)

Author keywords

HCV; HIV; HIV HCV co infection; peginterferon alfa 2a; randomized controlled trial; ribavirin

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; ZIDOVUDINE; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GENETICS; HEPATITIS C VIRUS; MIDDLE AGED; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84864323143     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1303-142     Document Type: Article

References (23)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
2. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-355.
3. Jacobson IM, Brown RS, Jr., McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007;46(4):982-990. (Pubitemid 350144762)
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-450. (Pubitemid 38988593)
5. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839- 2848. (Pubitemid 39628231)
6. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9(2): 82-88. (Pubitemid 351228130)
7. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21(9):1073-1089. (Pubitemid 46763278)
8. Nunez M, Miralles C, Berdun MA, et al. Role of weightbased ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23(8):972-982. (Pubitemid 47492337)
9. Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr. 2010;55(5):597-605.
10. Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. The incidence, predictors and management of anaemia and its association with virological response in HCV/HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther. 2011;33(11):1234-1244.
11. Ramos B, Nunez M, Rendon A, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat. 2007;14(6):387-391. (Pubitemid 46744049)
12. Opravil M, Rodriguez-Torres M, Rockstroh J, et al. The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIVHCV. HIV Clin Trials. 2012;13(1):33-45.
13. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451-459. (Pubitemid 38988594)
14. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003;37(6):1343-1350. (Pubitemid 36667314)
15. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39(6):1702-1708. (Pubitemid 38702672)
16. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350(22):2265-2271. (Pubitemid 38669209)
17. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131(2):470-477. (Pubitemid 44142464)
18. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360(3):257-267.
19. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
20. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100-1104.
21. Tanaka Y, Nishida N, Sugiyama M, et al. Genomewide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-1109.
22. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801.
23. Brau N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology. 2004;39(4):989-998. (Pubitemid 38428938)